Infectious Mononucleosis and CMV Panel

The Infectious Mononucleosis and CMV Panel is a blood test that measures selected antibodies to Epstein-Barr virus, or EBV, and cytomegalovirus, or CMV. It is used to support the assessment of symptoms consistent with infectious mononucleosis or another mononucleosis-like viral illness and to help distinguish recent infection from previous exposure.

The panel does not provide a diagnosis on its own. Antibody findings must be interpreted together with the timing of symptoms, physical examination, previous test results, medical history, pregnancy status, immune status and any additional laboratory findings.

What the panel includes

• EBV EA/VCA IgG, an IgG antibody marker related to EBV early and viral capsid antigens
• EBV EBNA IgG, IgG antibodies to the EBV nuclear antigen
• EBV VCA IgM, IgM antibodies to the EBV viral capsid antigen
• CMV IgG, antibodies generally associated with previous exposure to CMV
• CMV IgM, antibodies that may be detected during a recent or active immune response to CMV

This is an antibody panel. It does not include EBV or CMV PCR, CMV IgG avidity, a complete blood count, liver enzymes or a heterophile antibody test.

When the panel may be considered

Testing may be considered when symptoms and clinical findings raise suspicion of infectious mononucleosis. Possible features include fever, sore throat, swollen lymph nodes, malaise and persistent fatigue and low energy. Some people may also experience systemic symptoms such as headaches, migraines and dizziness, although these symptoms are not specific to EBV or CMV infection.

The panel may also be useful when a previous screening test was negative or unclear, when the clinical presentation is not typical, or when the physician needs a broader serologic assessment of a mononucleosis-like syndrome.

Why CMV is included in the differential assessment

EBV is the most commonly recognized viral cause of infectious mononucleosis, but CMV can produce a similar illness, particularly in otherwise healthy adults. CMV infection may cause fever, marked tiredness, malaise and laboratory changes that resemble EBV-associated mononucleosis. Sore throat and prominent lymph node enlargement may be less pronounced, but symptoms alone cannot reliably identify the responsible virus.

Including CMV IgG and IgM helps assess another relevant cause when the illness resembles mononucleosis but the EBV antibody pattern does not support a recent primary EBV infection. Other infections and noninfectious conditions can also produce similar symptoms, so negative EBV and CMV serology does not end the diagnostic process when symptoms remain unexplained.

How antibody findings relate to the infection phase

EBV antibody pattern

EBV VCA IgM usually appears early in primary infection and commonly becomes undetectable within several weeks. A positive VCA IgM result together with absent EBNA IgG can support a recent primary EBV infection when the symptoms and clinical findings are compatible.

EBV EBNA IgG generally appears later, often weeks to months after the beginning of infection, and usually remains detectable long term. Its presence, particularly with IgG reactivity and without VCA IgM, more often supports a past EBV infection rather than the earliest phase of primary infection.

EBV EA/VCA IgG may be detected during acute infection, but IgG antibodies can remain present after recovery. Antibodies to early antigen may also persist in some healthy people. This marker should therefore not be used alone to determine whether EBV is responsible for current symptoms. Very early infection can occasionally produce negative or equivocal serology, and repeat testing may be considered if clinical suspicion remains high.

CMV antibody pattern

CMV IgG usually indicates previous exposure to CMV. CMV IgM may be present with a recent or active immune response, but a positive IgM result alone cannot confirm a primary CMV infection or establish its exact timing. IgM may persist, recur during reactivation or occasionally be affected by nonspecific reactivity.

When CMV IgG and IgM are both positive, interpretation depends on symptoms, previous results and the clinical context. If precise dating is important, additional testing such as CMV IgG avidity, comparison with a later blood sample or molecular testing may be recommended. These additional tests are not part of this panel.

How the test is performed

Step 1: Clinical context

Before testing, it is helpful to note when the symptoms began, whether fever, sore throat or swollen lymph nodes are present, and whether previous EBV, CMV, blood count or liver test results are available.

Step 2: Blood sample

No special preparation is required. A blood sample is collected during a short laboratory appointment and sent for serologic analysis.

Step 3: Antibody analysis

The sample is tested for the five EBV and CMV antibody markers included in the panel. The complete report is generally issued within 5-7 business days.

Step 4: Medical interpretation

The results should be reviewed as a combined antibody pattern rather than as five unrelated positive or negative values. A physician may recommend additional blood tests, repeat serology, CMV avidity testing, PCR or another diagnostic pathway depending on the findings and the patient group.

Important limitations and next steps

This panel is primarily a serologic assessment for EBV and CMV. It is not sufficient by itself for diagnosing congenital CMV infection, evaluating a newborn, monitoring a transplant recipient or assessing possible viral reactivation in an immunocompromised patient. These situations require specialist-directed testing.

For a practical inquiry, include the date symptoms started, current symptoms, pregnancy or immune status when relevant, and any available laboratory reports. ZagrebMed can help clarify the testing pathway and organize the appropriate next step in Zagreb.